S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:AVXL

Anavex Life Sciences (AVXL) Stock Price, News & Analysis

$5.11
-0.17 (-3.22%)
(As of 04:00 PM ET)
Today's Range
$4.99
$5.35
50-Day Range
$4.92
$9.91
52-Week Range
$4.80
$10.45
Volume
1.00 million shs
Average Volume
1.47 million shs
Market Capitalization
$419.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

Anavex Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
685.9% Upside
$40.00 Price Target
Short Interest
Bearish
24.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.63) to ($0.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.64 out of 5 stars

Medical Sector

280th out of 948 stocks

Biological Products, Except Diagnostic Industry

43rd out of 158 stocks


AVXL stock logo

About Anavex Life Sciences Stock (NASDAQ:AVXL)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

AVXL Stock Price History

AVXL Stock News Headlines

AVXL Mar 2024 6.000 put
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
AVXL Mar 2024 4.000 call
AVXL Feb 2024 7.000 call
AVXL Feb 2024 4.500 call
Anavex Life Sciences Corporation
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Anavex Life Sciences Earnings Preview
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
Anavex Life Sciences Corp (AVXL)
Anavex: The Pediatric Rett Trial Failure Is Disastrous
Anavex: The Pediatric Rett Trial Failure Is Disastrous
See More Headlines
Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/04/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AVXL
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$40.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+635.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-47,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.73 per share

Miscellaneous

Free Float
72,588,000
Market Cap
$446.68 million
Optionable
Optionable
Beta
0.58
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Christopher U. Missling M.B.A. (Age 58)
    M.S., Ph.D., President, CEO, Secretary & Director
    Comp: $828.25k
  • Ms. Sandra Boenisch CPA (Age 43)
    CGA, Principal Financial Officer & Treasurer
    Comp: $194.36k
  • Mr. Stephan Toutain M.B.A. (Age 58)
    M.S., Senior VP of Operations & COO
  • Dr. Walter E. Kaufmann M.D.
    Chief Scientific Officer
  • Clint Tomlinson
    VP of Corporate
  • Dr. Adebayo Laniyonu Ph.D.
    Senior Vice President of Nonclinical Development
  • Dr. Edward R Hammond M.D.
    M.P.H., Ph.D., Chief Medical Officer
  • Dr. Kun Jin Ph.D.
    Head of Biostatistics
  • Mr. David Goldberger R.Ph.
    Senior Vice President of Regulatory Affairs














AVXL Stock Analysis - Frequently Asked Questions

Should I buy or sell Anavex Life Sciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVXL shares.
View AVXL analyst ratings
or view top-rated stocks.

What is Anavex Life Sciences' stock price target for 2024?

1 equities research analysts have issued 1-year price objectives for Anavex Life Sciences' stock. Their AVXL share price targets range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 685.9% from the stock's current price.
View analysts price targets for AVXL
or view top-rated stocks among Wall Street analysts.

How have AVXL shares performed in 2024?

Anavex Life Sciences' stock was trading at $9.31 at the beginning of the year. Since then, AVXL shares have decreased by 45.3% and is now trading at $5.09.
View the best growth stocks for 2024 here
.

When is Anavex Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AVXL earnings forecast
.

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its quarterly earnings results on Wednesday, February, 7th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04.

What ETF holds Anavex Life Sciences' stock ?

iShares Neuroscience and Healthcare ETF holds 9,668 shares of AVXL stock, representing 1.85% of its portfolio.

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), SharkNinja (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.31%), DLD Asset Management LP (0.00%), Nwam LLC (0.97%), Northern Trust Corp (0.90%), Charles Schwab Investment Management Inc. (0.76%) and SG Americas Securities LLC (0.37%). Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch.
View institutional ownership trends
.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVXL) was last updated on 3/4/2024 by MarketBeat.com Staff